Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Medical technologies major C. R. Bard, Inc. (BCR - Analyst Report) entered a definitive agreement to acquire a leading developer and supplier of plant based hemostatic agents Medafor, Inc. C. R. Bard has agreed to purchase the privately-held company for $200 million at a closing date later this year, In addition, BCR will provide future contingent payments up to $80 million based on revenue-based milestones through Jun 30, 2015.

The transaction is formed as a merger and has been approved by boards of directors of both the companies. However, it is subject to an approval by Medafor’s shareholders and customary regulatory review.

The acquisition will help Bard gain access to a proprietary technology platform and expand its global footprint. It will boost the company’s surgical specialties portfolio (particularly surgical hemostats) in its Davol subsidiary.

Medafor has many promising future products in the pipeline. C.R. Bard expects the acquisition to contribute about 1% to revenue growth in 2014, and a few cents to adjusted earnings per share in 2013 but neutral to 2014.

Medafor is famous for its Arista MPH Hemostat agent, which controls bleeding and reduce hemorrhage when conventional means become ineffective or impractical. Arista is a plant-based platform using Microporous Polysaccharide Hemospheres technology that has been proved to be safe, effective and convenient to use in many surgical procedures.

Surgical hemostats provide greater visibility of the surgical site and reduce postoperative complications and the potential for costly transfusions. Currently, the global market for surgical hemostats is over $1.4 billion.

C.R. Bard reported adjusted earnings of $1.42 per share in the second quarter of the year and beat the Zacks Consensus Estimate by 4 cents. Revenues increased 2% (3% at constant exchange rate or CER) on a year-over-year basis to $759.9 million and surpassed the Zacks Consensus Estimate of $751 million.

BCR expects revenue growth in the range of 1%–3% at CER, excluding any royalties from the Gore litigation in the third quarter of 2013. The company expects adjusted earnings in the range of $1.37 to $1.41 a share in the quarter.

Currently, BCR carries a Zacks Rank #3 (Hold). Other medical stocks that are worth considering include Alphatec Holdings, Inc. (ATEC - Snapshot Report), The Cooper Companies Inc. (COO - Analyst Report) and Align Technology Inc. (ALGN - Analyst Report). They carry a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
BITAUTO HOLD BITA 35.28 +14.66%
ANI PHARMACE ANIP 24.64 +13.97%
E HOUSECHINA EJ 11.01 +9.44%
CANADIAN SOL CSIQ 26.90 +6.87%
KNIGHTSBRIDG VLCCF 12.47 +5.50%